[ORGANIZATION]
Compass Pathways
Featured in 4 tracked stories · first seen
Situations
COMPASS Pathways psilocybin therapy development
2 clusters · 5 sources · last updated
Latest: Compass Pathways prepares FDA submission for psilocybin therapy
Biotechnology company COMPASS Pathways is advancing its lead candidate, COMP360, a synthetic psilocybin formulation designed to treat treatment-resistant depression. In mid-September 2026, the company reported a Q2 finan
Eli Lilly therapeutic pipeline expansion
2 clusters · 3 sources · last updated
Latest: Eli Lilly expands research in dermatology and psychedelics
Eli Lilly has been pursuing strategic expansions into new therapeutic fields, specifically mental health, immunology, and dermatology. In September 2026, the company completed its acquisition of AtaiBeckley, a biopharmac
Also covered in
-
MAHA Summit addresses chronic disease and healthcare innovation
[HEALTH] · 2 sources ·